Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2023 16:05 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

BASKING RIDGE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
March 23, 2023 08:30 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
February 01, 2023 08:30 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Participation in Upcoming Conferences in February

BASKING RIDGE, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
November 10, 2022 16:05 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Conference call scheduled for today at 4:30 p.m. Eastern time Post-merger profile describes rich clinical development pipeline backed by solid financial situationQilu Pharmaceutical Phase 1b/2 study...
November 07, 2022 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Participation in Upcoming Conferences in November 2022

BASKING RIDGE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
November 03, 2022 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
October 06, 2022 08:30 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Participation in Upcoming Conferences in October 2022

BASKING RIDGE, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...
September 29, 2022 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research Award

BASKING RIDGE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...
September 15, 2022 09:15 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board...
September 14, 2022 08:00 ET | Source: Caladrius Biosciences, Inc.

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by...